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Strengths and limitations of this study
 ► This prospective cohort comprehensively examines 
biopsychosocial health problems encountered by 
Chinese older patients with multimorbidity in a pri-
mary care programme in Hong Kong. As far as we 
are aware of, very few prospective cohorts specif-
ically cover this population in primary care, and no 
such prospective cohort exists among Chinese.
 ► The data could be linked with electronic health re-
cords to allow follow- up and examination of long- 
term outcomes associated with multimorbidity and 
predictors of those outcomes.
 ► The limitation was that older adult patients who 
were male, disabled, very ill, institutionalised or 
housebounded were less likely to have participated 
in this study; a few assessments were only con-
ducted within subgroups or added at a later stage; 
the sample size may limit examinations of potential 
interactions and factors associated with multimor-
bidity in some subgroups.
 ► The baseline health results had been weighted 
according to the census data. The weighted rates 
might be an underestimation of the rates among the 
primary care patients and be close to the rates of the 
general population.
AbStrACt
Purpose This is an ongoing prospective cohort aiming to 
examine the biopsychosocial health profiles and predictors 
of health outcomes of older patients with multimorbidity in 
primary care in Hong Kong.
Participants From April 2016 to October 2017, 1077 
patients aged 60+ years with at least two chronic diseases 
were recruited in four public primary care clinics in the 
New Territories East Region of Hong Kong.
Findings to date After weighting, the patients had 4.1 
(1.8) chronic conditions and 2.5 (1.9) medications on 
average; 37% forgot taking medication sometimes; 71% 
rated their health as fair or poor; 17% were frail; 73% 
reported one (21%) or two or more (52%) body pain areas; 
62% were overweight/obese; 23% reported chewing 
difficulty, 18% reported incontinence; 36% had current 
stage 1/2 hypertension; 38% had handgrip strength below 
the cut- off; 10% screened positive in sarcopenia; 17% had 
mild or severer cognitive impairment; 17% had mild to 
severe depression; 16% had mild to severe anxiety; 50% 
had subthreshold to severe insomnia; 28% indicated being 
lonely; 12% needed help in at least one out of the five daily 
functions and the EuroQoL-5- Dimensions-5- Level index 
score was 0.81 (0.20) and its Visual Analogue Scale (VAS) 
score was 67.6 (14.6). In the past 12 months, 17% were 
hospitalised, 92% attended general outpatient clinics, 70% 
attended specialist outpatient clinics and 10% used elderly 
daycare centre services, the median out- of- pocket health 
cost was HK$1000 (US$150). Female and male patients 
showed significant differences in many biopsychosocial 
health aspects.
Future plans With assessments and clinical data, 
the cohort can be used for understanding longitudinal 
trajectories of biopsychosocial health profiles of Chinese 
older patients with multimorbidity in primary care. We are 
also initially planning cohort studies on factors associated 
with various health outcomes, as well as quality of life and 
healthcare use.
Cohort registration number ChiCTR- OIC-16008477
IntroduCtIon
Multimorbidity, defined as patients living 
with two or more chronic health conditions, 
is common in primary care. The prevalence is 
increasing over the last decades as a result of 
an ageing population and changes in lifestyles, 
for example, more sedentary lifestyle which 
have increased the risk of obesity, resulting 
in a higher risk of developing chronic condi-
tions.1 2 A recent systematic review suggests 
that the prevalence of multimorbidity is high 
among the elderly ranging from 12.9% to 
95.1% in different studies.3 Multimorbidity 
is associated with increased disability and 
depression, reduced quality of life and higher 
rates of adverse drug consequences.4 Multi-
morbidity also leads to increased primary and 
secondary health service utilisation, especially 
unplanned healthcare, as well as reduced 
life expectancy.5 The direct and indirect 
economic burden associated with multimor-
bidity is huge.6 The annual healthcare costs 
were €4096.86 among patients with five or 
more chronic conditions, which was almost 
five times more than those who were healthy 
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Figure 1 Flow chart of recruitment.
in a study in the West of Ireland.7 It has been estimated 
that by 2030, 66% of the global disease burden will be due 
to chronic diseases, with most of the burden occurring in 
the most populous area—Asia.8 9 The economic burden 
highlights an urgent need for holistic understanding of 
patients with multimorbidity when searching for cost- 
effective ways to manage these patients, given that treat-
ment of diseases in isolation can be inefficient, leading to 
duplication of care and poorer health outcomes.10
Studies on multimorbidity have increased in recent 
years,11–20 and a clinical guideline on clinical assessment 
and management of multimorbidity was developed by the 
National Institute for Health and Care Excellence in the 
UK in 2016.21 However, studies are still needed for the 
epidemiology and profiles of patients with multimorbidity 
and their longitudinal outcomes to inform policy- making 
in different populations including Chinese primary 
care patients.3 11 Most studies on primary care patients 
with multimorbidity are conducted in western countries 
such as UK, USA, Australia, Spain and Belgium,14 15 22–28 
and limited research has been conducted on psycho-
logical and social problems accompanying with multi-
morbidity.3 11 21 29 30 Several longitudinal studies of 
multimorbidity have been conducted in Asian popula-
tions,31–33 but none of these are of primary care patients. 
Important knowledge gaps still exist regarding the biopsy-
chosocial health profiles of patients with multimorbidity 
in primary care among Asian Chinese.34 Therefore, more 
studies among Chinese patients with multimorbidity in 
primary care are needed to advance our understanding 
for services.14 35–39
This study focuses on the elderly in Hong Kong, where 
the population is ageing rapidly. Hong Kong has a 
population of 7.34 million according to the 2016 census 
data, with 23.7% aged 60 years or above. The rate was 
higher than the proportions in 2006 (16.5%) and 2011 
(19.5%).40 In Hong Kong, although there is a large 
private primary care sector, around 85% of people with 
chronic conditions are managed in the public primary 
care setting. Given that the Hong Kong population has 
the longest life expectancy in the world: (81.7 for men 
and 87.7 for women in 2017),41 the ageing population 
and multimorbidity have brought much burden and chal-
lenge to the local healthcare system. To inform health-
care providers and policy- makers in allocating suitable 
health services for people with multimorbidity in primary 
care, the present study aimed to study the longitudinal 
biopsychosocial health profiles and also predictors of 
health outcomes of Chinese patients with multimorbidity 
who present to public primary care in Hong Kong.
Cohort deSCrIPtIon
Study setting and participants
This study contains primary care patients from four 
general outpatient clinics (GOPCs) out of the 10 general 
outpatient clinics (GOPCs) in the New Territory East 
Cluster (NTEC), Hong Kong, as permission to recruit 
from these four clinics was given by the local regulator (the 
Hospital Authority) during the study period. Each GOPC 
receives about 450 patients each day. The working hours 
are generally from 9:00 to 17:00 hours from Monday to 
Friday with some additional night and weekend sessions. 
In the most recent Hospital Authority Annual Report 
2016–2017, the 10 GOPCs in NTEC provided 972 454 
consultations in total in the year of 2015/2016, which 
consisted of one- third of total GOPC consultations in 
Hong Kong public health system.42
The inclusion criteria of participants were: (1) aged 
60 years or above; (2) with two or more chronic diseases 
confirmed by the medical information in the public clin-
ical management system and patients’ self- report and 
(3) could speak and understand Chinese. No specific 
exclusion criteria were adopted. However, as participants 
needed to respond to questionnaire surveys and health 
checks, they should be able to access the clinic, sign 
informed consent by themselves, and understand and 
answer the research questions.
Patients were first consecutively screened for eligibility 
by trained research assistants in the waiting areas of the 
GOPCs. For those who were eligible, they were asked to 
provide a contact phone number and then were sched-
uled to visit the study nurse for further assessments. 
All patients provided informed consent before partici-
pation in the study. From April 2016 to October 2017, 
1077 eligible patients were recruited and completed 
the baseline assessments. The baseline assessments were 
conducted through face- to- face interviews by nurses or a 
social worker at a university affiliated primary care clinic. 
The flow chart of recruitment is shown in figure 1. The 
sample size allows a margin of error at 3% with a 95% 
CI. It is also 100% powered to detect a mean difference 
of 0.5 (assuming SD is 1.0) and 90% powered to detect a 
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Table 1 Core topic areas in questionnaires and examinations of the study
Assessment Description
Questionnaire
Use of medication No and duration (0–1 year/2–5 years/>5 years) for antihypertensive, cardiovascular and 
hypolipidaemic drugs, antidiabetics, antipsychotics and analgesics.
Compliance of medication use ‘At times, do you forget to take your prescription medications?’ (no/yes)
Depression The 2- item Patient Health Questionnaire (PHQ-2) for depression; The 9- item PHQ (PHQ-9) for 
those with PHQ-2 ≥3.
Anxiety The 2- item Genralised Anxiety Disorder (GAD-2); The 7- item GAD (GAD-7) for those with GAD-
2 ≥3.
Loneliness* The 6- item De Jong Gierveld Loneliness Scale; and one question asking ‘Do you feel lonely? 
(yes/no)’ (added at a later stage)
Insomnia The 7- item Insomnia Severity Index for those answered yes to the screening question ‘In the 
past 2 weeks, do you have insomnia? (yes/no)’
Pain A screening question of ‘In the past year, do you have musculoskeletal pain for at least 3 
months’, for those who answered ‘yes, one pain area or ‘yes, two or more pain areas’, Brief 
Pain Inventory was measured.
Physical activity For those were screened positive in pain, Physical Activity Scale for the Elderly was measured.
Self- rated health ‘In general, how will you describe your health? (extremely good, very good or good/fair/poor)’
Community network ‘When you need help, do you have someone who is willing to and able to meet your needs?’ 
(always/sometimes/never)
Meaning of existence* One item extracted from the validated reliable Chinese Purpose in Life test: “My personal 
existence is utterly meaningless and purposeless vs. very meaningful and purposeful”, 
assessed by a 7- point Likert scale with 1 denoting the lowest level and 7 denoting the highest 
level of perceived meaning of existence.
Use of social media A screening question of ‘In the past 2 weeks, have you ever used the following social media’, 
for those who answered yes to any of the social media, they were further assessed with 
importance and comfort of using internet.
Oral health* ‘Do you have any difficulty when biting or chewing foods (even with the use of denture)’ (yes/
no)
Incontinence* ‘Do you have incontinence?’ (yes/occasionally/no)
Frailty* The Edmonton Frail Scale.
Sarcopenia* The 5- item Sarcopenia Assessment.
Cognition Mainly assessed with Montreal Cognitive Assessment Hong Kong version but in an earlier 
stage, Abbreviated Memory Inventory for Chinese was used.
Quality of life The EQ- 5D- 5L
Daily function Instrumental Activities of Daily Living including ability to use telephone, mode of transportation, 
shopping, food preparation, ability to handle finances.
Use of health services Visits to primary care doctors, specialist outpatient clinics, admission to hospital, use of 
services in elderly daycare centres and out- of- pocket healthcare cost both in private and 
public in the past year.
Alcohol use The 3- item Alcohol Use Disorders Identification Test- consumption for those who drank alcohol 
in the past year.
Tobacco use One question asking for current, ex- smoking and non- smoking behaviour.
Caregiving to somebody else ‘Are you taking care of somebody?’ (yes/no)
Social economic status Age, gender, marriage, living status, employment, receiving of social welfare scheme.
Physical examination
Blood pressure Measured twice in 15 min after rest.
Body mass index
Waist circumference
Handgrip strength Each hand was measured twice.
Continued
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Assessment Description
Electronic health record and 
self- report data
Chronic diseases 43 common chronic conditions in 15 categories including:
1. Metabolic diseases (hypertension, lipid disorder, diabetes).
2. Cancer.
3. Disease of the cardiovascular system (coronary heart disease, stroke/cerebrovascular 
disease, peripheral vascular disease).
4. Disease of the respiratory system (COPD, bronchiectasis, asthma, chronic pharyngitis /
laryngitis).
5. Disease of the liver, spleen and gallbladder (gallbladder/spleen disease, viral hepatitis, 
chronic liver disease).
6. Disease of the stomach and intestines (dyspepsia and gastritis, diverticular disease of 
intestine, chronic enteritis; irritable bowel syndrome; constipation).
7. Disease of the musculoskeletal and connective tissue (chronic pain needing medication 
control, skeletal and connective tissue inflammation (such as arthritis, gout)).
8. Disease of the genitourinary system (chronic kidney disease (nephritis), prostatitis, benign 
prostatic hyperplasia).
9. Disease of the ear, nose and throat (chronic rhinitis, deafness/tinnitus).
10. Disease of the visual system (glaucoma/cataracts, blindness/amblyopia, diabetic eyes, 
retinal detachment).
11. Disease of the skin (eczema, psoriasis).
12. Disease of the blood (anaemia).
13. Disease of the nervous system (multiple sclerosis, migraine, epilepsy, Parkinson’s disease).
14. Mental disorders (schizophrenia/bipolar disorder, depression, anxiety and other stress- 
related disorders, dementia).
15. Others.
Use of medication Medication use number and duration (0–1 year/2–5 years/>5 years) for antihypertensive drugs, 
cardiovascular drugs, cholesterol- lowering drugs, antidiabetics, antipsychotics and analgesics
*Measures were added at later stages: about 712–995 patients received these measures.
COPD, Chronic obstructive pulmonary disease; EQ- 5D- 5L, EuroQoL-5- Dimensions-5- Level.
Table 1 Continued
difference of 8% of different rates, with a follow- up rate 
of 50% (α=0.05).43 44
Measures
The assessments covered a range of measures that are 
postulated to be potential physical, psychological and 
social factors associated with multimorbidity. Each 
complete assessment lasted for about 45–60 min. All the 
measures were validated and have been widely used or 
have been used in our previous studies. Information 
was collected through face- to- face interviews by trained 
nurses, social workers and research assistants, and addi-
tional information of the disease entities, medication use 
and health service utilisation was confirmed through the 
review of electronic medical records by nurses. The elec-
tronic medical records include patient information and 
diagnosis, health examinations, medication prescription 
and health visits to the public health system. The records 
cover all patients who seek medical services in public 
health system. It is a medical record system of routine 
clinical practices with quality ensured by all healthcare 
professionals including trained doctors, nurses and allied 
health professionals under Hospital Authority in Hong 
Kong.
The measures in the questionnaires included: (1) the 
number and type of chronic diseases in fifteen catego-
ries (a total of 43 chronic conditionals) adapted slightly 
by a group of family physicians and researchers based on 
chronic conditions employed in previous studies45 46 and 
the International Statistical Classification of Diseases 11. 
Details can be seen in table 1; (2) depression (screened 
by the 2- item Patient Health Questionnaire (PHQ-2)).47 
Those with a score of 3 or more (which suggests depres-
sion) were further measured by the 9- item PHQ (PHQ-9)48; 
(3) anxiety (screened by the 2- item Generalised Anxiety 
Disorder (GAD-2)). Those with a score of 3 or more 
(which suggests anxiety) were further measured by the 
7- item GAD (GAD-7)49; (4) loneliness (measured by the 
6- item De Jong Gierveld Loneliness Scale),50 as well as one 
loneliness question; (5) insomnia (measured by the 7- item 
Insomnia Severity Index)51 among those who answered 
yes to a screening question); (6) pain (measured by the 
Brief Pain Inventory among those who were screened 
positive in pain); (7) physical activity (measured by Phys-
ical Activity Scale for the Elderly (PASE)52 among those 
who were screened positive in pain); (8) frailty (measured 
by the Edmonton Frail Scale53 which was translated and 
back- translated by experienced bilingual translators); (9) 
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meaning of existence (measured by one question extracted 
from the validated Chinese Purpose in Life test which was 
used in a previous study)54; (10) sarcopenia (measured 
by the 5- item Sarcopenia Assessment)55 56; (11) cognition 
(measured by the Hong Kong Montreal Cognitive Assess-
ment (HK- MoCA) with a score of 22 or above being with 
normal cognition)57; (12) alcohol use (screened by one 
question and then measured by the 3- item Alcohol Use 
Disorders Identification Test- consumption for those who 
screened positive); (13) smoking (non- smoker, current 
smoker, ex- smoker); (14) medication use (number and 
duration (0–1 year/2–5 years/>5 years) of antihyper-
tensive, cardiovascular and hypolipidaemic drugs, anti-
diabetics, antipsychotics and analgesics was checked in 
electronic medical system, and compliance of medica-
tion use was measured by ‘At times, do you forget to take 
your prescription medications?’ (no/yes)); (15) self- 
rated health; (16) community network; (17) use of social 
media (measured by a screening question, and for those 
who answered yes to any of the social media, they were 
further assessed on the importance and comfort of using 
the internet); (17) oral health; (18) incontinence; (19) 
caregiving to somebody; (20) quality of life (measured by 
the EuroQoL-5- Dimensions-5- Level (EQ- 5D- 5L))58; (21) 
daily function (ability to use the telephone, mode of trans-
portation, shopping, food preparation, ability to handle 
finances were measured); (22) health service utilisation 
(visits to primary care doctors, specialist outpatient clinics 
(SOPC), admission to hospital, use of services in elderly 
daycare centres and out- of- pocket healthcare costs which 
were not covered by public health system or insurance 
both in private and public in the past year). In addition, 
physical examinations included blood pressure, body mass 
index (BMI), waist circumference and handgrip strength 
(kg). For blood pressure, two assessments were taken by 
the nurses. Patients sat for at least 5 min before the first 
assessment, and they were assessed again 15 min later. 
Handgrip strength was also assessed twice for each hand. 
Social economic status, such as age, gender, marriage, 
living status, employment, receiving of social welfare 
scheme, was also included. Due to the data collection 
plan amendments, a few measures were only collected in a 
subgroup of the patients at a later stage. Summaries of the 
baseline measures are described in table 1.
The questionnaire was set up in password protected 
EpiData files in a password- protected computer with 
quality control. For example, for scale questions with 
answers on a Likert scale of 1–5, a range of 1–5 and one 
digit was set up so no other results were allowed during 
data entry. Additionally, for most data variables, a ‘must 
enter’ was set up, so that the question could not be missed 
unless answered or an individual purposely moves to the 
next question. Checking for missing data was done regu-
larly by experienced researchers and missing data was 
further collected by nurses through face- to- face inter-
views, telephone or by checking the electronic medical 
record system.
Patient and public involvement
The research questions and outcome measures were 
developed based on some most common problems that 
are widely recognised among elder patients. Patients 
or the public did not involve in the design of the study, 
recruitment or conduction of the study. The results of 
the study would be disseminated to patients once he or 
she requests so and aggregated data would be reported 
in project reports and research publications and 
conferences.
Findings to date
Baseline characteristics of the patients in the study are 
shown in table 2. The weighted data are shown in the 
bracket beside the unweighted data. The mean age of 
the study patients was 70 (SD=6.8) (70.5, SD=7.9) years, 
70% (53%) were female, 67% (68%) were married, 14% 
(15%) lived alone, 92% (87%) were retired or house-
wives, 49% (52%) had 6 years of education or above, 10% 
(10%) were on the Comprehensive Social Security Assis-
tance scheme which is open for those with a low income, 
about half used social media in the last 2 weeks, about 18% 
(15%) provided care to another (such as their spouse or 
children/grandchildren), 13% (17%) had drank alcohol 
in the past year and 3% (4%) were current smokers. More 
female patients lived alone, were retired/housewives, 
had lower education and more received social security 
support than male patients (p values <0.05).
After weighting, overall, the mean number of chronic 
diseases was 4.1 (SD=1.8) and about one in five patients 
had six or more chronic diseases. The top three chronic 
conditions were hypertension (75%), dyslipidaemia 
(46%), and skeletal and connective tissue inflammation 
(eg, arthritis) (36%). The unweighted and weighted 
prevalence of comorbidities of the 15 disease categories 
among the patients is shown in figures 2 and 3, respec-
tively. The unweighted and weighted comorbidities of 
top 10 prevalent conditions out of the 43 conditions are 
shown in figures 4 and 5, respectively, with the combina-
tion of hypertension and dyslipidaemia being the most 
common (39%), followed by hypertension and diabetes 
mellitus (27%), hypertension and skeletal and connective 
tissue inflammation (eg, arthritis) (26%), dyslipidaemia 
and diabetes mellitus (21%), hypertension and chronic 
pain (20%). Information of the rest comorbidities is 
shown in the figures. Female patients had fewer number 
of chronic conditions, fewer number of medications 
in use but poorer self- rated health than male patients 
(p<0.05). On average, patients took 2.5 (SD=1.9) medica-
tions, with 30% taking five or more medications regularly, 
36% reported forgot taking medication sometimes.
After weighting, the mean BMI was 24.3 (SD=3.4) with 
62% being overweight or obese. Based on the Edmonton 
Frail Scale, 17% were frail. Ten per cent had sarco-
penia, 23% reported chewing difficulty, 17% reported 
incontinence, 36% had stage one or two hypertension 
currently according to the physical examination, 38% 
had their handgrip strength (based on the best outcome 
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Figure 2 Unweighted prevalence of comorbidities (by 15 disease categories) among the 1077 elderly with multimorbidity 
(figures are unweighted (%)). CVD, cardiovascular disease; ENT, ear, nose and throat; GI disease, gastrointestinal disease; MSK, 
musculoskeletal disorders.
Figure 3 Weighted prevalence of comorbidities (by 15 disease categories) among the 1077 elderly with multimorbidity (figures 
are weighted prevalence (%)). CVD: cardiovascular disease; ENT, ear, nose and throat; GI disease: gastrointestinal disease; 
MSK: musculoskeletal disorders.
of two trials of both hands) below the cut- off point, 12% 
needed help or were dependent in at least one out of 
the five daily functions (using telephone, transporta-
tion, shopping, preparing meals or financial manage-
ment). Overall, 30%, 59% and 11% of patients rated 
their health being ‘excellent/very good/good’, ‘fair’ 
or ‘poor’, respectively. Seventy- three per cent reported 
the presence of one (21%) or two or more (52%) body 
pain areas, 17% scored the HK- MoCA <22 suggesting 
at least mild cognitive impairment; 18% had PHQ-2 ≥3, 
while 17% had PHQ-9 ≥5 suggesting mild depression or 
more severe; 15% had GAD-2 ≥3, while 16% had GAD-7 
≥5 suggesting mild anxiety or more severe; 50% had 
insomnia at subthreshold level or above, the mean score 
of the meaning of existence was 4.9 (SD=1.2) out of 7, 
28% reported feeling lonely. More finding details can be 
seen in table 2. More female patients had incontinence, 
pain, sarcopenia and cognitive impairment than male 
patients. Female patients were more likely to be screened 
positive in depression and anxiety, reported severer level 
of insomnia and reported lower perceived existence of 
meaning than male patients. Female patients were more 
likely to be frail. More male patients used social media 
(p<0.05). The loneliness level and perceived social 
support were not significantly different between female 
and male patients.
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Figure 4 Unweighted prevalence of the comorbidities of top 10 chronic conditions (out of 43 specific chronic conditions) 
among the 1077 elderly with multimorbidity (figures are unweighted prevalence (%)).
Figure 5 Weighted prevalence of the comorbidities of top 10 chronic conditions (out of 43 specific chronic conditions) among 
the 1077 elderly with multimorbidity (figures are weighted prevalence (%)).
In addition, after weighting, the EQ- 5D- 5L index score 
was 0.81 (0.20) and its Visual Analogue Scale score was 
67.6 (14.6) out of 100. Female patients showed poorer 
quality of life. In the last year, 17% were admitted to 
hospital, 92% attended GOPC, 70% attended SOPC, 
10% used elderly day care centre services and the median 
out- of- pocket health cost was HK$1000 (US$150) for any 
health expenditures not covered by the public health 
system or insurance. Male patients reported more GOPC 
visits than female patients in the past year (p=0.007).
Future plans
The patients will be followed up regularly (interval of ~2 
years) to monitor changes in health status and outcomes 
through data collected from questionnaires, physical 
assessments and clinical records. Key biopsychosocial 
assessments such as depression, anxiety, loneliness, pain, 
frailty, as well as quality of life would be included in the 
follow- up assessments, but each follow- up might be added 
with some additional assessments with specific research 
interests. The first follow- up (ie, wave 2 assessment) had 
started in early 2018. Additional information on mobility 
by the 30 s chair- stand test, visual acuity by Amsler Grid 
test and hearing by Weber’s test and Rinne Test were 
added. Information on electronic medical records will 
also be updated to provide information on health service 
utilisation, changes in medication use and new onset of 
diseases and death.
The longitudinal trajectories of biopsychosocial health 
profiles of these primary care patients will be described. 
For example, changes and occurrence of different 
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physical, mental and social problems among all the study 
participants as well as some subgroups (eg, different age, 
gender, comorbidities). We are also initially planning 
cohort studies on factors associated with various health 
outcomes as well as quality of life and healthcare use. In 
addition, more explorations will be made to answer many 
other research questions based on hypotheses.
Strengths and limitations
This study has several strengths. First, this is one of the 
few aetiological studies on older adults being conducted 
in Asian primary care settings to examine physical, 
psychological and social problems accompanying with 
multimorbidity. Second, it prospectively covers a range 
of biopsychosocial factors, which are not included in 
other previous large- scale studies since plenty of them 
are derived from extracted medical or insurance records. 
Our findings suggest that people with multimorbidity 
have significant complex healthcare needs in physical, 
mental and social aspects such as obesity, multiple body 
pain, polypharmacy, depression, anxiety, insomnia and 
loneliness. The results suggested that a holistic approach 
that addresses general physical and functional domain 
of health, at the same time assessing and managing 
psychological and social problems is therefore needed 
in the care of older adults with multimorbidity. Services 
which are designed to cater for the complex needs of 
elder patients with multimorbidity from biopsychosocial 
perspectives are urgently needed. These service models 
should also be adapted and tested in local circumstances 
to maximise its efficacy. Furthermore, given the signifi-
cant differences found between male and female patients 
in biopsychosocial aspects, future interventions may also 
need to take gender differences into account. Third, 
the results were weighted according to the census data 
to make the sample more representative of the general 
population. In general, the weighted results were similar 
to the unweighted results, and in consistency with results 
reported in the western populations. Fourth, because it 
contains linked electronic medical records, it will allow 
us to follow them up for public medical service use and 
mortality.
There are also several limitations. First, self- selection 
bias might still exist which was consistent with other 
similar studies,59 although we used weighting for adjust-
ment, as not all variables were available for weighting 
such as education. Since only ambulatory adults who 
agreed to join were recruited and these usually are more 
likely to be female and those with higher educational 
level and higher self- motivation, and those who were 
housebound or institutionalised are less likely to have 
been included, we might have resulted in a relatively 
healthier and higher- functioning patients in primary 
care, and the real health status might be worse than 
what are reported in our study. Future studies may need 
to take measures to increase participation from male 
and vulnerable patients. Second, the sample size may 
limit examinations of potential interactions and factors 
associated with multimorbidity in some subgroups such 
as older men and patients with lower educational levels, 
or uncommon health problems. Third, we used a two- 
step assessment for some health indicators. While false 
negative reported rates of pain, insomnia and alcohol 
use were unlikely, there might be false negative rates for 
depression and anxiety as the specificity and sensitivity of 
PHQ-2 and GAD-2 were not 100% (although results from 
meta- analytical reviews suggest they are reasonable to use 
in initial screening).49 60 In addition, as PHQ-2 and GAD-2 
are often used for screening with results in dichotomies 
(negative/positive), this might limit application of some 
statistical analysis such as using growth models in future 
longitudinal data. Fourth, for a few assessments, we only 
conducted them among a subgroup of participants, for 
example, PASE for physical activity among those patients 
with pain. Furthermore, some additional assessments 
such as meaning, sarcopenia, oral health were added at 
a later stage. So only subgroup data could be reported 
in this paper or analysed in the future when using these 
data.
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